Privacy rights and drug law: a recurring constitutional theme

The right to privacy has become one of the most consequential — and contested — constitutional arguments in drug-law reform worldwide. From Bogotá to Anchorage to Cape Town, courts have been asked whether the state may criminalise what an adult does in private with their own body and mind. The answers have varied, but the question itself has reshaped how democracies think about prohibition, personal autonomy, and the limits of state power. For substances such as psilocybin, which remains strictly prohibited in South Africa and many other jurisdictions, the privacy argument is not yet a live legal doctrine — but it is a recurring theme that is increasingly difficult for lawmakers and courts to ignore.

The constitutional architecture of privacy

Privacy rights appear in most modern constitutions and human rights instruments, though their exact scope remains far from settled. The South African Constitution (Section 14) explicitly protects privacy, including the right not to have one's person or home searched, one's property searched, one's possessions seized, or the privacy of one's communications infringed. Similar protections exist under the European Convention on Human Rights (Article 8), the Canadian Charter of Rights and Freedoms (Section 7, covering life, liberty, and security of the person), and various state constitutions in the United States.

What privacy means in the context of drug law is a harder question. Privacy arguments in drug cases generally rest on a few related ideas: that adults have a sphere of personal autonomy into which the state should not reach; that what a person does privately in their own home, with their own body, is fundamentally their own concern; and that criminal punishment for purely personal, private conduct is a disproportionate intrusion on that sphere. Critics of this framing argue that drug use is never purely private — it carries social, health, and economic ripple effects — and that the state has a legitimate interest in protecting individuals and communities from harm. Courts have generally had to weigh both perspectives.

South Africa's cannabis precedent

South Africa's most significant drug-privacy ruling came in 2018, when the Constitutional Court held in *Minister of Justice and Constitutional Development v Prince* that criminalising the possession, cultivation, and use of cannabis by adults in private for personal consumption was an unjustifiable infringement of the right to privacy. The judgment did not legalise cannabis in any commercial sense; it removed criminal penalties for private, personal use only, leaving the broader regulatory framework intact.

The case had a long legal history. Garreth Prince, a Rastafari, had challenged cannabis prohibition as early as 2002, arguing that religious use of cannabis was protected under constitutional rights to freedom of religion and privacy. The Constitutional Court ruled against him at the time, finding the limitation justified. But the privacy argument returned — this time successfully — in a 2017 Western Cape High Court judgment that the Constitutional Court later substantially affirmed. The Court's reasoning emphasised that an adult's right to engage in personal, private conduct in their own home deserves constitutional protection, and that criminalisation was too blunt an instrument for the state's stated aims.

The judgment has been described as a landmark, but its scope remains debated. Parliament was ordered to amend the law, and the subsequent legislative process — producing the Cannabis for Private Purposes Act — took years, passing only in 2024. Implementation and regulation remain a subject of ongoing political and legal contestation.

Comparative privacy rulings

South Africa is not alone in having seen courts apply privacy reasoning to drug laws. In 1975, the Alaska Supreme Court ruled in *Ravin v State* that the state constitution's privacy protections extended to the personal possession and use of small amounts of cannabis by adults in the home. This was not a federal ruling and did not apply outside Alaska, but it made the state's cannabis policy distinctive for decades.

In Colombia, the Constitutional Court ruled in 1994 (Decision C-221/94) that personal consumption of drugs was protected under the right to the free development of personality, effectively decriminalising personal use. The Court reasoned that adults have the right to make decisions about their own lives, including decisions about drug use, so long as they do not harm others. This ruling has survived subsequent political challenges, though Colombia's broader drug policy remains complex.

In Canada, the Ontario Court of Appeal's 2000 ruling in *R v Parker* found that prohibiting medical cannabis violated the Charter rights of patients. While the case was primarily about medical access rather than privacy in the recreational sense, it invoked Section 7's protection of life, liberty, and security of the person — a closely related principle. The federal government subsequently created a medical cannabis regulatory framework.

Not every privacy challenge has succeeded, however. Courts in several US states have rejected privacy arguments for drug use, and the US Supreme Court has generally declined to recognise a constitutional right to use controlled substances under federal privacy doctrines. The picture is uneven, and outcomes often depend on the specific constitutional text, the jurisdiction, and the substance involved.

Limits and recurring tensions

One reason privacy arguments have had mixed success is that courts routinely balance privacy against other constitutional values — public health, public safety, and the state's duty to protect vulnerable people. Under the South African Constitution's Section 36 limitation clause, rights can be restricted if the limitation is reasonable and justifiable in an open and democratic society. Courts must weigh the nature and importance of the right, the purpose of the limitation, and whether less intrusive means could achieve the same end.

This balancing act produces recurring tensions. Privacy advocates argue that criminalising personal, private use is a disproportionate response to public health concerns, and that education, harm reduction, and health-based approaches are less intrusive alternatives. Those favouring continued criminalisation — or at least strict regulation — argue that drug use carries enough risk of harm to individuals and society to justify state intervention, and that privacy rights were never intended to shield conduct with significant public consequences.

A further complication is that privacy rulings typically apply only to personal, private use. They rarely extend to commercial supply, distribution, or public use. This creates a legal grey zone: conduct that is no longer criminal in private may still be criminal in public, and the supply chain that makes private use possible remains prohibited. Courts and legislatures have struggled to resolve this tension, and it remains one of the most discussed problems in drug-policy reform scholarship.

What this could mean for psilocybin

Psilocybin is currently classified as a Schedule 7 substance in South Africa under the Medicines and Related Substances Act, placing it among the most strictly controlled substances in the country. Any legal challenge to this classification on privacy grounds would face significant hurdles. Courts would need to be persuaded that private, personal use of psilocybin is constitutionally analogous to private, personal use of cannabis, and that the state's interests in maintaining prohibition do not justify the intrusion on privacy.

The cannabis precedent provides a template, but not a guarantee. Cannabis had decades of litigation, shifting public opinion, and a growing body of medical evidence behind it before the Constitutional Court ruled. Psilocybin's evidence base is expanding — particularly in mental health research — but its legal and cultural trajectory is at a much earlier stage. Privacy arguments may eventually feature in challenges to psilocybin prohibition, as they have with cannabis, but the constitutional reasoning would need to be built case by case, and the outcomes are far from certain.